NRC Form 374A (8-82) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 23-12255-02

Docket or Reference number 30-9360

Amendment No. 13

Veterans Administration Medical Center
Biloxi, Mississippi 39531

In accordance with letter and attachments dated April 13, 1983, License Number 23-12255-02 is amended as follows:

To add:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
E. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	E. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	F. As necessary for uses authorized in Subitem 9.E.
F. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	F. Any radiopharmaceutical listed in Group V of Schedule A. Section 35.100 of 10 CFR 35	F. As necessary for uses authorized in Subitem 9.F.

9. Authorized use

E. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

F. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

Conditions 12. and 16. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Frank L. Schmidt, M.D.	Groups I, II and III In vitro studies Xenon 133
Laura M. Sauls, M.D.	Groups I, II and III In vitro studies Xenon 133
Daniel B. Gordon, M.D.	Groups I, II and III In vitro studies Xenon 133

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 23-12255-02

Docket or Reference number

Amendment No. 13

12. continued

Pararajasingam Jeyarajah, M.D.	Groups I, II and III In vitro studies Xenon 133
John L. Campbell II, MD.	Groups I, II, III, IV and V In vitro studies Xenon 133

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated April 10, 1978; letters dated January 26, 1979, May 4, 1979, April 23, 1981 and November 2, 1981; application dated December 22, 1981; letter dated April 6, 1982; Model ALARA Program contained in Appendix O of Regulatory Guide 10.8 (Rev. 1), "Guide for the Preparation of Applications for Medical Programs," October 1980; letter dated January 10, 1983; letter and attachments dated April 13, 1983. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

Condition 20. is added:

20. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

JUN 07 1983

Original signed by
F. A. St. Mary

Date _____

By Material Licensing Branch
Division of Fuel Cycle and Material Safety
Washington, D. C. 20555

J. M. Taylor June 3, 1983

F.A. 6/6/83

WH

NRC Form 374A (8-82) U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 2 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
23-12255-02

Docket or Reference number
30-9360

Amendment No. 14

Condition 21. is added:

21. The licensee may use the Lineator device for doing linearity tests of his dose calibrator provided he follows the procedures in the Atomic Products Corporation Lineator Instructions Manual dated June 20, 1983.

APR 23 1984

Date _____

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By _____
Material Licensing Branch
Division of Fuel Cycle and
Material Safety
Washington, D. C. 20555

4/23/84

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
23-12255-02

Docket or Reference number
30-7360

Amendment No. 12

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated April 10, 1978; letters dated January 26, 1979, May 4, 1979, April 23, 1981 and November 2, 1981; application dated December 22, 1981; letter dated April 6, 1982; Model AIARA Program contained in Appendix O of Regulatory Guide 10.8 (Rev. 1), "Guide for the Preparation of Applications for Medical Programs," October 1980; and letter dated January 10, 1983. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

Condition 19. is added:

19. The Radiation Protection Officer for the activities authorized by this license is John L. Campbell II, M.D.

FEB 15 1983

Date

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

2/10/83

By

Material Licensing Branch
Division of Fuel Cycle and
Material Safety
Washington, D. C. 20555

2/10/83